Fidelity Investments
ALDX icon

Fidelity Investments’s Aldeyra Therapeutics ALDX Stock Holding History

Fidelity Investments’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.9K Buy
16,503
+9,538
+137% +$41.8K ﹤0.01% 4377
2025
Q4 		$36.1K Buy
6,965
+366
+6% +$1.88K ﹤0.01% 4241
2025
Q3 		$34.4K Buy
6,599
+17
+0.3% +$89 ﹤0.01% 4137
2025
Q2 		$25.2K Sell
6,582
-3,651
-36% -$9.44K ﹤0.01% 4200
2025
Q1 		$58.8K Sell
10,233
-538
-5% -$3.18K ﹤0.01% 3788
2024
Q4 		$53.7K Buy
10,771
+12
+0.1% +$62 ﹤0.01% 3819
2024
Q3 		$58K Buy
10,759
+1,612
+18% +$7.67K ﹤0.01% 3727
2024
Q2 		$30.3K Buy
9,147
+1,479
+19% +$5.79K ﹤0.01% 3872
2024
Q1 		$25.1K Buy
7,668
+1,061
+16% +$3.49K ﹤0.01% 3918
2023
Q4 		$23.2K Buy
6,607
+1,653
+33% +$5.1K ﹤0.01% 3867
2023
Q3 		$33.1K Sell
4,954
-676,304
-99% -$5.02M ﹤0.01% 3558
2023
Q2 		$5.72M Sell
681,258
-107,531
-14% -$1.06M ﹤0.01% 2029
2023
Q1 		$7.83M Sell
788,789
-177,287
-18% -$1.25M ﹤0.01% 1967
2022
Q4 		$6.72M Sell
966,076
-84,383
-8% -$482K ﹤0.01% 2032
2022
Q3 		$5.61M Buy
1,050,459
+375,875
+56% +$2.26M ﹤0.01% 2128
2022
Q2 		$2.69M Buy
674,584
+670,651
+17,052% +$2.31M ﹤0.01% 2413
2022
Q1 		$17K Buy
3,933
+3,834
+3,873% +$15.3K ﹤0.01% 4061
2021
Q4 		$0 Sell
99
-1,201,911
-100% -$9.17M ﹤0.01% 4283
2021
Q3 		$10.6M Sell
1,202,010
-86
-0% -$789 ﹤0.01% 2109
2021
Q2 		$13.6M Buy
1,202,096
+442,302
+58% +$5.32M ﹤0.01% 1993
2021
Q1 		$9.03M Buy
759,794
+631,306
+491% +$7.27M ﹤0.01% 2067
2020
Q4 		$881K Sell
128,488
-32,045
-20% -$225K ﹤0.01% 2554
2020
Q3 		$1.19M Sell
160,533
-451,600
-74% -$2.92M ﹤0.01% 2399
2020
Q2 		$2.55M Sell
612,133
-594,600
-49% -$2.17M ﹤0.01% 2223
2020
Q1 		$2.98M Sell
1,206,733
-134,900
-10% -$607K ﹤0.01% 2091
2019
Q4 		$7.79M Sell
1,341,633
-100
-0% -$578 ﹤0.01% 1934
2019
Q3 		$7.07M Sell
1,341,733
-251,600
-16% -$1.35M ﹤0.01% 1944
2019
Q2 		$9.56M Sell
1,593,333
-302,300
-16% -$2.27M ﹤0.01% 1895
2019
Q1 		$17.1M Sell
1,895,633
-668,700
-26% -$5.68M ﹤0.01% 1665
2018
Q4 		$21.3M Hold
2,564,333
– – ﹤0.01% 1529
2018
Q3 		$35.4M Buy
2,564,333
+953,022
+59% +$7.73M ﹤0.01% 1439
2018
Q2 		$12.8M Hold
1,611,311
– – ﹤0.01% 1870
2018
Q1 		$12.1M Hold
1,611,311
– – ﹤0.01% 1905
2017
Q4 		$11M Hold
1,611,311
– – ﹤0.01% 1929
2017
Q3 		$11.6M Sell
1,611,311
-43,000
-3% -$225K ﹤0.01% 1891
2017
Q2 		$7.78M Sell
1,654,311
-51,000
-3% -$235K ﹤0.01% 2032
2017
Q1 		$8.53M Sell
1,705,311
-92,500
-5% -$476K ﹤0.01% 2030
2016
Q4 		$9.62M Hold
1,797,811
– – ﹤0.01% 1986
2016
Q3 		$14.1M Hold
1,797,811
– – ﹤0.01% 1847
2016
Q2 		$10.2M Buy
1,797,811
+360,000
+25% +$2.01M ﹤0.01% 1955
2016
Q1 		$6.02M Hold
1,437,811
– – ﹤0.01% 2105
2015
Q4 		$9.75M Hold
1,437,811
– – ﹤0.01% 2000
2015
Q3 		$8.38M Hold
1,437,811
– – ﹤0.01% 2020
2015
Q2 		$11.2M Buy
1,437,811
+603,000
+72% +$5.2M ﹤0.01% 1965
2015
Q1 		$8.66M Hold
834,811
– – ﹤0.01% 2050
2014
Q4 		$6.03M Hold
834,811
– – ﹤0.01% 2167
2014
Q3 		$5.02M Hold
834,811
– – ﹤0.01% 2228
2014
Q2 		$5.53M Buy
+834,811
New +$5.61M ﹤0.01% 2217

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments's ALDX Position: Q1 2026 in Review

Fidelity Investments increased its Aldeyra Therapeutics (ALDX) stake by 137% in Q1 2026, buying an estimated $41.8K and bringing the position to 16,503 shares worth $27.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4377.

Fidelity Investments first reported a position in ALDX in Q2 2014 and has held it in 48 quarters since. The position peaked at $35.4M in Q3 2018. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Fidelity Investments held 16,503 shares of Aldeyra Therapeutics worth $27.9K as of Q1 2026.
  • Fidelity Investments bought 9,538 Aldeyra Therapeutics shares in Q1 2026, an estimated $41.8K.
  • Aldeyra Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4377 holding.
  • Fidelity Investments first reported a position in Aldeyra Therapeutics in Q2 2014 and has held it in 48 quarters since.
  • Fidelity Investments's Aldeyra Therapeutics position peaked at $35.4M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.